Results for tag: "Edoxaban"

Edoxaban is a direct oral anticoagulant (DOAC) used to treat and prevent blood clots in patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is a member of the factor Xa inhibitor class of drugs, which work by blocking the action of factor Xa, an enzyme involved in the clotting process. Edoxaban is approved for use in the United States, Europe, and Japan, and is marketed under the brand name Lixiana. Edoxaban is a relatively new drug in the hematological drugs market, but it has been gaining traction due to its efficacy and safety profile. It is seen as a viable alternative to warfarin, the traditional anticoagulant, which has a number of drawbacks. Edoxaban is also seen as a potential treatment for other hematological conditions, such as thrombocytopenia and thrombotic thrombocytopenic purpura. The companies in the Edoxaban market include Daiichi Sankyo, Bayer, and Pfizer. Show Less Read more